Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial

Trial Profile

Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Artemether/lumefantrine (Primary) ; Artesunate/amodiaquine (Primary) ; Dihydroartemisinin/piperaquine (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Acronyms TETRDC2016
  • Most Recent Events

    • 10 Apr 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 10 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 10 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top